Use of cardiotrophin in liver diseases
CA 2461007 C · Owner: Lasarte Sagastibelza, Juan Jose · Inventors: Bustos De Abajo, Matilde; Lasarte Sagastibelza, Juan Jose; Baixeras Llano, Elena
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of cardiotrophin in liver diseases. The invention describes the increased expression of cardiotrophin (CT-1) during the process of hepatic regeneration coinciding with maximum proliferation of hepatocytes and the role of CT-1 as a stimulator of hepatic regeneration. Furthermore it describes the , hepatoprotective , role of CT-1 in various models of acute liver damage. The importance of using CT-1 in the manufacture of compositions for use in the treatment of hepatopathies is demonstrated. The invention describes such use in , various forms and methods, including the recombinant protein and the use of the , gene sequences that code for CT-1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 20, 2002 and granted February 11, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.